<DOC>
	<DOCNO>NCT02115269</DOCNO>
	<brief_summary>Headaches common medical problem physician frequently encounter practice . One key find The Atlas Headache Disorders prepare World Health Organization ( WHO ) : headache disorder , include migraine tension-type headache ( TTH ) , among prevalent disorder mankind . The fixed combination indomethacin , prochlorperazine caffeine ( IndoProCaf ) show efficacy safety acute treatment migraine episodic tension-type headache attack . IndoProCaf ( Difmetre® ) widely used common daily practice Italy early 1970s , available Commonwealth Independent States ( CIS ) pharmaceutical market . There limited data regard IndoProCaf usage post-marketing setting . This first post-marketing observational study aim evaluate effectiveness patient ' satisfaction primary headache acute treatment routine clinical setting Ukraine Kazakhstan .</brief_summary>
	<brief_title>IndoProCaf Effervescent Tablets Effectiveness Acute Treatment Migraine and/or Episodic Tension-type Headache Patients ' Satisfaction With Treatment Routine Clinical Practice</brief_title>
	<detailed_description>The study design prospective , multicentre , observational , non-interventional , non-randomized , non-controlled , single arm , post-marketing study IndoProCaf prescribe usual manner per standard clinical practice treat physician accordance term locally approve instruction medical use . No additional procedure ( standard care ) shall apply patient .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Tension-Type Headache</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Headache Disorders</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<mesh_term>Headache Disorders , Primary</mesh_term>
	<criteria>Diagnosis primary headache ( migraine without aura and/or episodic TTH ) whose headache attack require acute pharmacological treatment . Were administer IndoProCaf ( Difmetre® ) effervescent tablet therapy accord local product labelling . Adults 18 year old ( male , female ) . Provide Authorization investigator use and/or disclose personal and/or health data . Meet contraindication treatment IndoProCaf ( Difmetre® ) effervescent tablet outline late version local product labelling . Patients required prescription physician IndoProCaf nonsteroidal antiinflammatory drugcontaining product time acute headache attack treatment . Previous discontinuation IndoProCaf treatment due safety ( i.e . hypersensitivity ) event , lack efficacy . Female patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Indoprocaf</keyword>
	<keyword>Indomethacin</keyword>
	<keyword>Caffeine</keyword>
	<keyword>Prochlorperazine</keyword>
	<keyword>Migraine Aura</keyword>
	<keyword>Migraine without Aura</keyword>
	<keyword>Tension-Type Headache</keyword>
</DOC>